A 21-day safety evaluation of biotechnologically produced 3-fucosyllactose (3-FL) in neonatal farm piglets to support use in infant formulas
Food and Chemical Toxicology · 2024
DOI: 10.1016/j.fct.2024.114592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2024. Verfasst von Jeffrey Pitt und 10 weiteren Autor:innen. Beteiligte Einrichtung: International Flavors & Fragrances, Larkin Laboratory, 1803 Larkin Center Drive, Midland, MI, 48642, USA. Electronic address: jeffrey.a.pitt@iff.com. Hauptthemen laut MEDLINE: Infant Formula, Milk, Human. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
3-Fucosyllactose (3-FL) is one of the most abundant fucosylated oligosaccharides in human breast milk and is an approved infant formula ingredient world-wide. 3-FL functions as a prebiotic to promote early microbial colonization of the gut, increase pathogen resistance and modulate immune responses. To investigate safety and potential gut microbiota effects, 3-FL was fed for 21-days to farm piglets beginning on Postnatal Day (PND) 2. Fructooligosaccharide (FOS), an approved infant formula ingredient, was used as a reference control. Standard toxicological endpoints were evaluated, and the gut microbiota were assessed. Neither 3-FL (245.77 and 489.72 mg/kg/day for males and 246.57 and 494.18 mg/kg/day for females) nor FOS (489.44 and 496.33 mg/kg/day males and females, respectively) produced any adverse differences in growth, food intake or efficiency, clinical observations, or clinical or anatomic pathology changes. Differences in the gut microbiota after 3-FL consumption (versus control and FOS groups) included the absence of Bifidobacterium species from the piglets, enrichment of Prevotellamassilia timonensis, Blautia species, Mediterranea massiliensis, Lachnospiraceae incertae sedis, and Eubacterium coprostanoligens and lower relative abundance of Allisonella histaminiformans and Roseburia inulinivorans. This study further supports the safe use of 3-FL produced using biotechnology as a nutritional ingredient in foods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Flavors & Fragrances, Larkin Laboratory, 1803 Larkin Center Drive, Midland, MI, 48642, USA. Electronic address: jeffrey.a.pitt@iff.com.
- Charles River (CR-MWN), 54943 N. Main Street, Mattawan, MI, 49071, USA; Labcorp Drug Development, 671 South Meridian Road, Greenfield, IN, 46140, USA.
- DuPont Stine-Haskell, 1090 Elkton Rd, Newark, DE, 19714, USA; Teva Pharmaceuticals, 145 Brandywine Parkway, West Chester, PA, 19380, USA.
- International Flavors & Fragrances, Leiden Bio Science Park, Galileiweg 8, 2333 BD, Leiden, the Netherlands.
- DuPont Stine-Haskell, 1090 Elkton Rd, Newark, DE, 19714, USA; Benson Hill, 1001 N Warson Rd, St. Louis, MO, 63132, USA.
- International Flavors & Fragrances, 3329 Agriculture Drive, Madison, WI, 53716, USA.
Zitieren
APA
Pitt, J., Bond, J., Roper, J., Tenning, P., Mukherjea, R., Evans, K., Saarinen, M. T., Anglenius, H., Hirvonen, J., Hasselwander, O., & Lim, A. (2024). A 21-day safety evaluation of biotechnologically produced 3-fucosyllactose (3-FL) in neonatal farm piglets to support use in infant formulas. Food and Chemical Toxicology. https://doi.org/10.1016/j.fct.2024.114592
Vancouver
Pitt J, Bond J, Roper J, Tenning P, Mukherjea R, Evans K, et al. A 21-day safety evaluation of biotechnologically produced 3-fucosyllactose (3-FL) in neonatal farm piglets to support use in infant formulas. Food and Chemical Toxicology. 2024. doi:10.1016/j.fct.2024.114592
BibTeX
@article{Pitt2024,
author = {Pitt, Jeffrey and Bond, Jennifer and Roper, Jason and Tenning, Paul and Mukherjea, Ratna and Evans, Kara and Saarinen, Markku T and Anglenius, Heli and Hirvonen, Johanna and Hasselwander, Oliver and Lim, Angela},
title = {A 21-day safety evaluation of biotechnologically produced 3-fucosyllactose (3-FL) in neonatal farm piglets to support use in infant formulas},
journal = {Food and Chemical Toxicology},
year = {2024},
doi = {10.1016/j.fct.2024.114592}
}
EUVIMED